4C Medical Technologies
4C Medical Technologies is a private, clinical-stage medical device company developing the AltaValve System, a supra-annular transcatheter mitral valve replacement device for treating mitral regurgitation in patients at high risk for open-heart surgery. The company is conducting the ATLAS pivotal trial in the US and Europe and is funded through a $175 million Series D led by Boston Scientific.
- Company typePrivate
- Founded2017
- HeadquartersMaple Grove, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What 4C Medical Technologies does
4C Medical Technologies, Inc. is a privately-held, venture-backed medical device company headquartered in Maple Grove, Minnesota, founded in 2015 and focused exclusively on minimally invasive transcatheter therapies for structural heart disease, specifically mitral regurgitation (MR). The company's single core product is the AltaValve System, a supra-annular transcatheter mitral valve replacement (TMVR) device whose differentiating architectural feature is atrial-only fixation: the device is positioned above the native mitral annulus rather than within the left ventricle, preserving the chordae tendineae, the native valve leaflets, and left ventricular geometry. Notable technical components include a dynamic stent designed for overexpansion fit across variable mitral annular anatomy, a fully recapturable delivery system usable until detachment, and a transseptal delivery profile with controlled steerability to accommodate heterogeneous patient anatomies.
The AltaValve is currently labeled an investigational device limited to investigational use under US federal law and is not yet commercially approved or sold. The company is generating no product revenue; its economics are funded through equity financings, with cumulative disclosed institutional capital exceeding $230 million across a ~$9 million convertible note led by Anges Québec (July 2017), a $17 million Series A (September 2018), a $35.4 million Series C led by MicroPort CardioFlow Medtech (March 2022), and a $175 million Series D led by Boston Scientific (March 2025). Go-to-market, once approved, is an enterprise field-sales motion targeting hospitals and cardiac specialty centers in the US and Europe, with pricing negotiated directly with healthcare institutions rather than publicly disclosed. The pivotal ATLAS trial commenced enrollment in October 2024 across both regions to support FDA and CE mark approval, and the company has begun building commercial-readiness capability through 2024 senior hires in therapy development and clinical affairs.
4C Medical Technologies firmographics
Firmographics- Name
- 4C Medical Technologies
- Legal name
- 4C Medical Technologies, Inc.
- Website
- https://4cmed.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- 4C Medical Technologies is a private, clinical-stage medical device company developing the AltaValve System, a supra-annular transcatheter mitral valve replacement device for treating mitral regurgitation in patients at high risk for open-heart surgery. The company is conducting the ATLAS pivotal trial in the US and Europe and is funded through a $175 million Series D led by Boston Scientific.
- Ownership category
- akta.pro rank
4C Medical Technologies industry classification
Industry- Product category
- Transcatheter Heart Valve Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
Keywords
Where 4C Medical Technologies is headquartered
LocationHeadquarters
- HQ city
- Maple Grove
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
4C Medical Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- AltaValve Medical Device Sales: Revenue generated from sale of AltaValve transcatheter mitral valve replacement devices to hospitals and cardiac centers for treatment of mitral regurgitation in patients who are high risk for open-heart surgery
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
4C Medical Technologies product offering
Product offeringCore offering
4C Medical Technologies develops and manufactures the AltaValve System, a supra-annular transcatheter mitral valve replacement (TMVR) device for the minimally invasive treatment of mitral regurgitation in patients at high risk for open-heart surgery. The company sells this implantable device and its delivery system directly to hospitals and cardiac specialty centers conducting structural heart procedures, with pivotal clinical trials underway to support regulatory approval in the US and Europe.
Product overview
4C Medical Technologies is a single-product medical device company focused on the AltaValve System, a next-generation transcatheter mitral valve replacement (TMVR) technology. The AltaValve System is supported by the ATLAS pivotal trial for regulatory approval and the Early Feasibility Study for initial clinical validation. The company is funded through Series D financing ($175M in 2025) and is advancing toward commercialization in the US and European markets.
Differentiator
Problem solved
Functional benefit
Brands
- AltaValve: A truly unique, supra-annular transcatheter mitral valve replacement (TMVR) system for treating mitral regurgitation. The first Mitral Regurgitation Therapy designed to expand the treatable patient population, streamline the procedure, and preserve critical cardiac structures.
Products and services
- AltaValve System A supra-annular transcatheter mitral valve replacement (TMVR) device with atrial-only fixation for treating mitral regurgitation; preserves the native mitral valve and left ventricle, expands the treatable patient population to include primary and secondary MR patients at high risk for open-heart surgery or transcatheter edge-to-edge repair, and is fully recapturable during deployment. Investigational device intended for hospitals and cardiac specialty centers.
Quantifiable outcome
- Nearly 10% of Americans aged 75+ affected by mitral regurgitation
- +1 more outcomes
Companies that use 4C Medical Technologies
Customer profileSegments1 record
Ideal customer profiles1 record
4C Medical Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
4C Medical Technologies partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights6 records
4C Medical Technologies competitors and assessment
Company assessmentDirect peers
- Medtronic: Develops the Intrepid transcatheter mitral valve replacement system as a direct competitor. Operates a large structural heart franchise (including transcatheter and surgical heart valves) with established hospital relationships globally.
- Edwards Lifesciences: Global leader in structural heart with the PASCAL Precision and EVOQUE transcatheter mitral valve replacement/repair systems. Direct competitor targeting the same MR patient population, with substantially larger commercial scale and R&D budget.
- Abbott: Acquired the Tendyne transcatheter mitral valve replacement system and competes directly in the TMVR space. Brings a global structural heart commercial infrastructure and capital resources far exceeding 4C Medical's.
Broad incumbents
- Boston Scientific: Lead investor in 4C Medical's Series D and a major structural heart incumbent with WATCHMAN, ACURATE, and other transcatheter platforms. Relevant both as a potential acquirer/commercialization partner and as a broad competitor with overlapping portfolios.
- LivaNova: Cardiac surgery and structural heart company with surgical heart valve franchises and prior mitral repair technology (e.g., Mitralign via divestiture). Relevant as a broad incumbent in cardiac surgery/valves that overlaps with 4C Medical's hospital call point and structural heart focus.
Emerging players
- MicroPort CardioFlow Medtech: Hong Kong-listed structural heart company (HKEX:2160) and lead Series C investor in 4C Medical. Develops transcatheter aortic and mitral valve products and represents a comparable emerging structural heart platform with China/global ambition.
- NeoVasc: Structural heart company developing the Tiara transcatheter mitral valve replacement system. Direct competitor in the TMVR space but earlier-stage than 4C Medical, making it a useful comparable on development trajectory.
- JenaValve Technology: Developer of transcatheter aortic valve replacement technology with structural heart overlap. Comparable as a venture/strategic-backed transcatheter valve company with overlapping IP and clinical development expertise.
- Ancora Heart: Developer of the AccuCinch transcatheter ventricular repair system for functional MR. Comparable as a venture-backed structural heart competitor pursuing a transcatheter MR solution via ventricular reshaping rather than valve replacement.
- Cardiac Dimensions: Developer of the Carillon mitral contour system, an indirect transcatheter approach to functional mitral regurgitation. Comparable as an emerging structural heart company pursuing MR via a different mechanism than 4C Medical's AltaValve.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
4C Medical Technologies social profiles
Digital presence4C Medical Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
4C Medical Technologies leadership team
Management profileNumber of profiles
Profiles10 records
4C Medical Technologies funding detail
Funding detailFunding overview
Funding rounds13 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
4C Medical Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 4C Medical Technologies
What does 4C Medical Technologies do?
4C Medical Technologies develops and manufactures the AltaValve System, a supra-annular transcatheter mitral valve replacement (TMVR) device for the minimally invasive treatment of mitral regurgitation in patients at high risk for open-heart surgery. The company sells this implantable device and its delivery system directly to hospitals and cardiac specialty centers conducting structural heart procedures, with pivotal clinical trials underway to support regulatory approval in the US and Europe.
Is 4C Medical Technologies a public or private company?
4C Medical Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was 4C Medical Technologies founded?
4C Medical Technologies was founded in 2017. It employs 11 to 50 people.
Where is 4C Medical Technologies based?
4C Medical Technologies is headquartered in Maple Grove, United States, in the North America region.
How does 4C Medical Technologies make money?
One revenue line is on record: altaValve Medical Device Sales.
Who are 4C Medical Technologies's main competitors?
Direct peers on record are Medtronic, Edwards Lifesciences and Abbott. Broad incumbents are Boston Scientific and LivaNova. Emerging players are MicroPort CardioFlow Medtech, NeoVasc, JenaValve Technology, Ancora Heart and Cardiac Dimensions.
Does 4C Medical Technologies have an API?
No public API is recorded for 4C Medical Technologies.
What industry is 4C Medical Technologies in?
4C Medical Technologies's product category is Transcatheter Heart Valve Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 339112 and its SIC code is 3841.